Skip to main content
. 2020 May;190(5):1018–1029. doi: 10.1016/j.ajpath.2020.01.013

Figure 3.

Figure 3

Evaluation of small and large intrahepatic bile duct mass (IBDM) and inflammation. A and B: With the use of cytokeratin (CK)-19 immunohistochemistry, no changes are observed between wild-type (WT) groups with regard to small and large IBDM; however, in multidrug-resistance transporter 2/ABC transporter B family member 2 knockout (Mdr2−/−) mice treated with mismatch, there is a significant increase in small and large IBDM (with large IBDM being significantly greater than small IBDM) compared with WT groups. Furthermore, when Mdr2−/− mice were treated with histamine-2 receptor (H2HR) vivo-morpholino, only large IBDM are significantly reduced (no significant changes are seen in small IBDM). Representative images (red arrows mark CK-19–positive bile ducts) (A) and semiquantification (B) are provided for all groups. C: Hepatic inflammation was determined by immunohistochemistry for F4/80 (Kupffer cell marker). The presence of Kupffer cells remains unchanged in WT groups versus Mdr2−/− mice treated with mismatch (WT H2HR mismatch = 5.065 ± 0.624; WT H2HR vivo-morpholino = 5.089 ± 0.946; Mdr2−/− H2HR mismatch = 4.904 ± 0.636). There is a reduction in mice treated with H2HR vivo-morpholino (3.182 ± 0.835); however, it is not significant when compared with Mdr2−/− mismatch. Data are expressed as means ± SEM. n = 10 representative images; n = 6 mice for each group. ∗P < 0.05 versus small and large IBDM from WT mismatch; †P < 0.05 versus large IBDM from Mdr2−/− + H2HR mismatch. Original magnification, ×40 (A and C).